Final safety and efficacy results from a phase 1/2 study of tagraxofusp, a CD123-targeted therapy, for myelofibrosis

By afschroeder • October 28, 2025

Yacoub A, Ali H, Gupta V, Wang ES, Patnaik MM, Schiller GJ, Taparia M, Mughal TI, Lindsay R, Galleu A, Gupta I, Pemmaraju N. Final safety and efficacy results from a phase 1/2 study of tagraxofusp, a CD123-targeted therapy, for myelofibrosis. Blood Neoplasia. 2025 Aug 25;2(4):100165. doi: 10.1016/j.bneo.2025.100165. PMID: 41146971; PMCID: PMC12554100.

Tags: Hematology/Oncology, Publications

Early-Onset Gastric Cancer as a High-Risk Disease Entity in the United States: Clinicopathologic Features, Regional Variation, and Outcomes

Castillo DR, Shah P, Tai D, Guo M, Hazeltine M, Guzman S, Park D, Mannan R, Xing Y, Brar G, Raoof M, Eng C, Wu[...]

Women and Herpes Zoster in the United States: Risk and Prevention Management-A Narrative Review

Campos R, Caldera F, Carrico J, Cochrane C, Eltoukhy N, Huang C, Kneller S, Rutland C, Slovis J. Women and Herpes Zoster in the United[...]

Newly Diagnosed VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome in a Patient Presenting With Legionella Pneumonia

Sanchez Jimenez A, Hirt C, Anand S, Tsai S, Ma J. Newly Diagnosed VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome in a Patient Presenting[...]